<DOC>
	<DOCNO>NCT00130533</DOCNO>
	<brief_summary>This prospective , open-label , randomized phase III study . Patients stratify per investigational site , previous adjuvant chemotherapy ( anthracyclines versus anthracyclines plus taxanes ) , number affect axillary lymph node ( 0 , 1-3 , &gt; = 4 ) . Node negative patient must present tumour size &gt; 2 cm eligible . At least 6 lymph node must analyse confirm number affect node . Patients randomise receive : 8 course capecitabine 1000 mg/m2 mouth , twice day ( p.o . bid ) 14 day , follow 7 day rest versus observation . Tissue sample must analyse central laboratory , confirm estrogen receptor ( ER ) , progesterone receptor ( PgR ) , human epidermal growth factor receptor-2 ( HER2 ) , cytokeratins CK 5/6 epidermal growth factor receptor ( EGFR ) status . The following data obtain database `` El Alamo '' project . One thousand six hundred twenty-seven ( 1,627 ) total consider year 1990 1997 . The population form patient operable breast cancer , surgery , positive node , negative hormone receptor , negative node , negative hormone receptor T2-3 tumor . For patient group , estimate 5-year disease-free survival 64.72 % . Assuming exponential distribution , aim detect increase 64.72 % 73.7 % 5 year Disease Free survival rate corresponds Hazard Ratio 0.701 risk reduction 30 % , power 80 % use two-tailed log-rank test 0.05 whereas 4 year recruitment period 3 year follow-up period . We would need 255 event , 834 patient without consider dropout . Considering drop-out rate 5 % post-randomization , final sample size 876 patient , 438 per treatment arm . The sample size calculation perform program package EAST version 5.2 .</brief_summary>
	<brief_title>Maintenance Treatment With Capecitabine Versus Observation Breast Cancer Patients</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<criteria>Written inform consent . Histological diagnosis operable invasive adenocarcinoma breast ( T1T3 ) . Tumours must HER2 negative . Time window end adjuvant chemotherapy study randomization must less 8 week . In patient receive adjuvant radiotherapy , time window allow last session randomisation 4 week . Surgery must consist mastectomy conservative surgery axillary lymph node dissection . Margins free disease ductal carcinoma insitu ( DCIS ) require . Lobular carcinoma consider positive margin . Node negative patient tumour size &gt; 2 cm . Positive axillary lymph node define least 1 6 node presence disease . If sentinel node technique use , sentinel node node affect . Patients belong follow classification eligible : pN1a , pN2a , pN3a . Status hormone receptor primary tumour . Negative result must available end adjuvant chemotherapy . Patients must present evidence metastatic disease . Negative status HER2 primary tumour , know randomization . Adjuvant chemotherapy consist minimum 6 course anthracyclines and/or taxanes . Age &gt; = 18 &lt; = 70 year old . Performance status ( Karnofsky index ) &gt; = 80 . Laboratory result ( within 14 day prior randomization ) : Hematology : neutrophil &gt; = 1.5 x 10e9/l ; platelet &gt; = 100x 10e9/l ; hemoglobin &gt; = 10 mg/dl Hepatic function : total bilirubin &lt; = 1 UNL ; SGOT SGPT &lt; = 2.5 UNL ; alkaline phosphatase &lt; = 2.5 UNL . If value SGOT SGPT &gt; 1.5 UNL associate alkaline phosphatase &gt; 2.5 UNL , patient eligible . Renal Function : creatinine &lt; = 175 Âµmol/l ( 2 mg/dl ) . creatinine clearance &gt; = 60 ml/min . Pharmacogenetics : one blood sample need SNPs assessment . Patients able comply treatment study followup . Negative pregnancy test do 14 previous day randomization . Prior therapy anthracyclines taxanes ( paclitaxel docetaxel ) malignancy . Pregnant lactating woman . Adequate contraceptive method must use chemotherapy hormone therapy treatment . Negative pregnancy test 14 previous day randomization . Bilateral invasive breast cancer . Any T4 M1 tumour . Axillary lymph node : patient belong follow classification exclude : pN1b , pN1c , pN2b , pN3b , pN3c . Any serious medical pathology , congestive heart failure , unstable angina , history myocardial infarction previous year , uncontrolled HA high risk arrhythmias . History neurological psychiatric disorder , could preclude patient free informed consent . Active uncontrolled infection . Active peptic ulcer , unstable diabetes mellitus . Previous current history neoplasms different breast cancer , except skin carcinoma , cervical situ carcinoma , tumour curatively treat without recurrence last 10 year ; ductal situ carcinoma breast ; lobular situ carcinoma . History hypersensitivity capecitabine , fluorouracil . Patients lack physical integrity upper gastrointestinal tract history bad absorption syndrome . History dihydropyrimidine dehydrogenase ( DPD ) deficiency . Anticoagulant treatment coumadin anticoagulant . Current treatment sorivudine chemical family . Concomitant treatment investigational product . Participation clinical trial nonmarketed drug 30 previous day randomization . Concomitant treatment therapy cancer . Males .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>TNBC Triple-Negative Early Breast Cancer</keyword>
	<keyword>Maintenance Adjuvant Chemotherapy</keyword>
	<keyword>Capecitabine</keyword>
	<keyword>Basal-like genotype</keyword>
</DOC>